Eastern Canadian Colorectal Cancer Consensus Conference: Application of new modalities of staging and treatment of gastrointestinal cancers

Current Oncology

Volumn 19, Issue 3, 2012, Pages 169-174

  di Valentin, T ^a   Alam, Y ^j   Ali Alsharm, A ^b   Arif, S ^h   Aubin, F ^l   Biagi, J ^b   Booth, C M ^b   Bourque, S ^p   Burkes, R ^c   Champion, P ^q   Colwell, B ^s   Cripps, C ^a   Dallaire, M ⁿ   Dorreen, M ^s   Finn, N ^o   Frechette, D ⁿ   Gallinger, S ^d   Gapski, J ^h   Giacomantonio, C ^r   Gill, S ^t   Goel, R ^a   Goodwin, R ^a   Grimard, L ^a   Grothey, A ^u   Hammad, N ^b   Hedley, D ^d   Jhaveri, K ^f   Jonker, D ^a   Ko, Y ^e   L'Esperance M ^k   Maroun, J ^a   Ostic, H ^b   Perrin, N ^k   Rother, M ^g   St Hilaire, E ^o   Tehfe, M ^l   Thirlwell, M ^m   Welch, S ⁱ   Yarom, N ^a   Asmis, T ^a   more..

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g Peel Regional Cancer Program   (Canada)

^h Trillium Health Centre Missassauga   (Canada)

ⁱ Trillium Health Centre ^*

^j Centre Regional De Cancerologie De Windsor   (Canada)

^k Centre Hospitalier   (Canada)

^l UNIVERSITÉ DE MONTRÉAL   (Canada)

^m MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁿ Hopital de Gatineau   (Canada)

^o Dr Léon Richard Oncology Center   (Canada)

^p HORIZON HEALTH NETWORK   (Canada)

^q Prince Edward Island   (Canada)

^r Capital Health Halifax   (Canada)

^s DALHOUSIE UNIVERSITY   (Canada)

^t BRITISH COLUMBIA CANCER AGENCY   (Canada)

^u MAYO CLINIC   (United States)

more..

Author keywords

Colorectal cancer; Consensus guideline; EGFRI; Microsatellites; Pancreatic cancer; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; TAXANE DERIVATIVE;

ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; COLORECTAL CANCER; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE MODIFICATION; METASTASIS; MICROSATELLITE INSTABILITY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 84930483742     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.931     Document Type: Article

References (33)

1. Vickers M, Samson B, Colwell B, et al. Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol 2010;17:70-7.
2. Canadian Task Force Methodology. New grades for recommendations from the Canadian Task Force on Preventive Health Care [Table 1]. CMAJ 2003;169:207-8. [Available online at: http://www.canadiantaskforce.ca/recommendations/2003_04_eng.html; cited April 30, 2012]
3. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
4. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (stepp), a phase ii, openlabel, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7.
5. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
6. Siena S, Tabernero J, Burkes RL, et al. Phase iii study (prime/20050203) of panitumumab (pmab) with folfox compared with folfox alone in patients (pts) with previously untreated metastatic colorectal cancer (mcrc): pooled safety data [abstract 4034]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35429; cited April 10, 2012]
7. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage ii and iii colon cancer. J Clin Oncol 2007;25:2205-11.
8. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5fu/lv in the adjuvant treatment of stage ii and stage iii colon cancer: efficacy results with a median follow-up of 4 years [abstract 167]. Am Soc Clin Oncol Gastrointest Cancer Symp 2005;:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=36&abstract ID=10254; cited April 10, 2012]
9. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7.
10. Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007;13:6359-68.
11. Gamelin L, Boisdron-Celle M, Morel A, Gamelin E. Oxaliplatin neurotoxicity [French]. Bull Cancer 2006;93(suppl 1):S17-22.
12. Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (ttf) in metastatic colorectal cancer (mcrc): final results of the phase iii concept trial [abstract 4010]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstract ID=34113; cited April 10, 2012]
13. Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatinrelated neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008;26:1188-9.
14. Nikcevich DA, Grothey A, Sloan JA, et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatininduced sensory neurotoxicity (snt) in adjuvant colon cancer: results of the phase iii placebo-controlled, doubleblind ncctg trial [abstract 4009]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstract ID=32445; cited April 10, 2012]
15. Stubblefield MD, Burstein HJ, Burton AW, et al. nccn task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 2009;7(suppl 5):S1-26.
16. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
17. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
18. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
19. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45:1890-6.
20. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5.
21. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007;25:4396-404.
22. Courneya KS, Sellar CM, Stevinson C, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009;27:4605-12.
23. Courneya, KS, Booth CM, Gill S, et al. The colon health and life-long exercise change (challenge) trial (co.21). Curr Oncol 2008;15:8-16.
24. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-19.
25. Marcaccio M, Langer B, Rumble B, Hunter A on behalf of the Expert Panel on hpb Surgical Oncology. Hepatic, Pancreatic, and Biliary Tract (HPB) Surgical Oncology Standards: Special Report. Toronto, ON: Cancer Care Ontario; 2006.
26. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
27. Cunningham D, Chau I, Stocken DD, et al. Phase iii randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-18.
28. Philip PA, Benedetti J, Corless C, et al. Phase iii study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed Intergroup trial S0205. J Clin Oncol 2010;28:3605-10.
29. Conroy T, Paillot B, François E. et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228-36.
30. Conroy T, Desseigne M, Ychou M, et al. Randomized phase iii trial comparing folfirinox (5fu/leucovorin, irinotecan and oxaliplatin) vs gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Prodige 4-accord 11/0402 trial: final results [abstract]. Ann Oncol 2010;21(suppl 8):viii251.
31. Conroy T, Desseigne F, Ychou M, et al. folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
32. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the conko 003 study [abstract 4508]. J Clin Oncol 2008;26:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55 &abstractID=34567; cited April 10, 2012]
33. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (bsc) versus oxaliplatin, folinic acid and 5-fluorouracil (off) plus bsc in patients for second-line advanced pancreatic cancer: a phase iii-study from the German conko-study group. Eur J Cancer 2011;47:1676-81.